Cardresearch

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

Phase 3, Completed, 2023, 399 people, 13 Nov 2023, clinicaltrials.gov